Navigation Links
Inovio Pharmaceuticals to Present at BIO CEO & Investor Conference
Date:2/4/2013

BLUE BELL, Pa., Feb. 4, 2013 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) announced today that CEO Dr. J. Joseph Kim will present an overview of the company at the 15th Annual BIO CEO and Investor Conference taking place February 11-12 at the Waldorf Astoria in New York City.

Inovio Presentation
February 12
9:30-10:00 a.m. EST
A live and archived webcast of the presentation will be available on Inovio's homepage.

About Inovio Pharmaceuticals, Inc.

Inovio is revolutionizing vaccines to prevent and treat today's cancers and challenging infectious diseases. Its SynCon® vaccines are designed to provide universal protection against known as well as new unmatched strains of pathogens such as influenza. These synthetic vaccines, in combination with Inovio's proprietary electroporation delivery, have been shown in humans to generate best-in-class immune responses with a favorable safety profile. Inovio's clinical programs include phase II studies for cervical dysplasia, leukemia and hepatitis C virus and phase I studies for influenza and HIV. Partners and collaborators include the University of Pennsylvania, Merck, ChronTech, National Cancer Institute, U.S. Military HIV Research Program, NIH, HIV Vaccines Trial Network, University of Southampton, US Dept. of Homeland Security, University of Manitoba and PATH Malaria Vaccine Initiative. More information is available at www.inovio.com.

This press release contains certain forward-looking statements relating to our business, including our plans to develop electroporation-based drug and gene delivery technologies and DNA vaccines and our capital resources. Actual events or results may differ from the expectations set forth herein as a result of a number of factors, including uncertainties inherent in pre-clinical studies, clinical trials and product development programs (including, but not limited to, the fact that pre-clinical and clinical results referenced in this release may not be indicative of results achievable in other trials or for other indications, that the studies or trials may not be successful or achieve the results desired, that pre-clinical studies and clinical trials may not commence or be completed in the time periods anticipated, that results from one study may not necessarily be reflected or supported by the results of other similar studies and that results from an animal study may not be indicative of results achievable in human studies), the availability of funding to support continuing research and studies in an effort to prove safety and efficacy of electroporation technology as a delivery mechanism or develop viable DNA vaccines, the adequacy of our capital resources, the availability or potential availability of alternative therapies or treatments for the conditions targeted by the company or its collaborators, including alternatives that may be more efficacious or cost-effective than any therapy or treatment that the company and its collaborators hope to develop, evaluation of potential opportunities, issues involving product liability, issues involving patents and whether they or licenses to them will provide the company with meaningful protection from others using the covered technologies, whether such proprietary rights are enforceable or defensible or infringe or allegedly infringe on rights of others or can withstand claims of invalidity and whether the company can finance or devote other significant resources that may be necessary to prosecute, protect or defend them, the level of corporate expenditures, assessments of the company's technology by potential corporate or other partners or collaborators, our ability to secure new partnerships and collaborations, capital market conditions, the impact of government healthcare proposals and other factors set forth in our Annual Report on Form 10-K for the year ended December 31, 2011, our Form 10-Q for the quarter ended September 30, 2012, and other regulatory filings from time to time. There can be no assurance that any product in Inovio's pipeline will be successfully developed or manufactured, that final results of clinical studies will be supportive of regulatory approvals required to market licensed products, or that any of the forward-looking information provided herein will be proven accurate.

CONTACTS:
Investors: Bernie Hertel , Inovio Pharmaceuticals, 858-410-3101, bhertel@inovio.com
Media: Jeff Richardson , Inovio Pharmaceuticals, 267-440-4211, jrichardson@inovio.com

(Logo: http://photos.prnewswire.com/prnh/20120131/LA44118LOGO)


'/>"/>
SOURCE Inovio Pharmaceuticals Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Inovios Synthetic Flu Vaccine Doubles Rate of Elderly Subjects Displaying Protective Immune Responses
2. Inovio Expands Synthetic Vaccine Intellectual Property License With University of Pennsylvania
3. Inovio Pharmaceuticals Reports 2012 Third Quarter Financial Results
4. Inovio Pharmaceuticals Takes Major Stride Toward Universal Influenza Vaccine
5. Inovio Pharmaceuticals Reports 2012 Second Quarter Financial Results
6. Inovio Pharmaceuticals Inc. Investor Presentation Now Available for On-demand Viewing at RetailInvestorConferences.com
7. Inovio Pharmaceuticals Inc. to Webcast, Live, at RetailInvestorConferences.com on August 2nd
8. Inovio Initiates H1N1 Universal Influenza Vaccine Clinical Trial Targeting Over-65 Population, Which Represents 90% of Flu Deaths
9. Inovio Pharmaceuticals to Present at JMP Investor Conference
10. Inovio Pharmaceuticals Universal Avian Flu Vaccine Generates Protective Antibody Responses Against Six H5N1 Viruses in Phase I Trial
11. Inovio Pharmaceuticals to Present at SPI 2012
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... and PUNE, India , March 24, 2017 ... Bone Stimulators Market: Global Opportunity Analysis and Industry Forecast, 2014-2022," the spine bone ... reach $724 million by 2022, growing at a CAGR of 3.6% during the ... ... Allied Market Research Logo ...
(Date:3/24/2017)... Research and Markets has announced the addition of ... report to their offering. ... Pain Management in the U.S.: Consumer ... pain, emphasizing consumer survey analysis, including trends over time. The ... have selected illnesses/conditions strongly associated with physical pain and pain ...
(Date:3/24/2017)... FinancialBuzz.com News Commentary  ... According to new data ... research, the legal cannabis market is projected to continue to ... signals from the current presidential administration. The report created by ... drivers of growth in this industry are the passage and ...
Breaking Medicine Technology:
(Date:3/24/2017)... ... ... Adventures of Joey, The Dog Who Barks at Puddles”: a boisterous story about a ... God intended. “The Adventures of Joey, The Dog Who Barks at Puddles” is the ... writing, especially about truth and human behavior. , Published by Christian Faith Publishing, Patti ...
(Date:3/23/2017)... ... March 23, 2017 , ... The physicians of KSF Orthopaedic Center ... Houston Area. The new location is located at 2255 E. Mossy Oaks Rd., Suite ... This newest location will provide patients living in the north Houston area (The Woodlands, ...
(Date:3/23/2017)... ... 2017 , ... PAINWeekEnd (PWE) Oklahoma City, on April 22 ... be an educational and exciting program providing busy clinicians and allied healthcare practitioners ... , Oklahoma is in a healthcare crisis. The state ranks 46th in America ...
(Date:3/23/2017)... ... 23, 2017 , ... 82% of adults are unaware of the dangers that infectious bacteria play ... the minimum two times a day that dentists recommend. The ramifications of improper oral upkeep ... school and adults missing 164 million hours of work each year due to dental issues. ...
(Date:3/23/2017)... ... March 23, 2017 , ... ... SmartBen NOW, an innovative mobile app and centralized benefits dashboard solving one of ... information securely from multiple locations. For the first time, employees can access up-to-date ...
Breaking Medicine News(10 mins):